Advertisement

Tumor Biology

, Volume 35, Issue 9, pp 9045–9051 | Cite as

Prognostic significance of VEGFR1/Flt-1 immunoexpression in colorectal carcinoma

  • Jaudah Al-Maghrabi
  • Wafaey Gomaa
  • Abdelbaset Buhmeida
  • Yousif Qari
  • Mohammad Al-Qahtani
  • Mahmoud Al-Ahwal
Research Article

Abstract

Colorectal carcinoma (CRC) is a major cause of morbidity and mortality. Vascular endothelial growth factor 1/Fms-like tyrosine kinase 1 (VEGFR1/Flt-1) regulates monocyte migration, recruits endothelial cell progenitors, increases the adhesive properties of natural killer cells and induces of growth factors. Flt-1 is expressed on tumour cells and has been implicated in tumour growth and progression. The objective of this study is to address the relation of Flt-1 expression to tumour prognostication. Paraffin blocks from 143 primary CRC and 48 regional nodal metastases were retrieved from the archives of the Department of Pathology at King Abdulaziz University. Tissue microarrays were designed and constructed. Immunohistochemistry for Flt-1 was performed. Staining intensity and extent of staining were assessed and combined. Results were dichotomised as low expression and high expression. Flt-1 was overexpressed in primary tumours and nodal metastasis (p < 0.001 and 0.001) with no difference between primary and nodal metastasis (p = 0.690). Flt-1 immunoexpression was not associated with the clinicopathological parameters. Flt-1 overexpression was an independent predictor of positive margin status, positive lymphovascular invasion and local disease recurrence (p < 0.001, p < 0.001 and p = 0.003, respectively). Flt-1 was not associated with survival (log-rank = 0.003, p = 0.959). Flt-1 was overexpressed in primary CRC and their nodal metastases. Flt-1 expression was an independent predictor of margin status, lymphovascular invasion and local disease recurrence. Therefore, expression profiling of Flt-1 seems to have a prognostic potential in CRC. However, to elucidate the association of overexpression of Flt-1 with tumour characteristics and prognostication, more in vivo and in vitro molecular investigations are recommended.

Keywords

CRC Flt-1 IHC Recurrence Metastasis 

Notes

Acknowledgments

This work was supported by Ministry of Higher Education and King Abdulaziz City for Science and Technology (KACST) grant 11-BIO1524-03 and the Scientific Chair for Colorectal Cancer, King Abdulaziz University, Jeddah, Saudi Arabia.

Conflicts of interest

None.

References

  1. 1.
    Huh JW, Kim HR, Kim YJ, Lee JH, Park YS, Cho SH, et al. Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int. 2009;59:241–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Al-Eid H, Arteh S Cancer incidence report of Saudi Arabia. 2009, pp 1-106.Google Scholar
  3. 3.
    Abajo A, Bitarte N, Zarate R, Boni V, Lopez I, Gonzalez-Huarriz M, et al. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. World J Gastroenterol. 2012;18:637–45.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87:3336–43.PubMedGoogle Scholar
  5. 5.
    Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 1996;271:17629–34.CrossRefPubMedGoogle Scholar
  6. 6.
    Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis. 2006;9:225–30. discussion 231.CrossRefPubMedGoogle Scholar
  7. 7.
    Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal. 2009;2:re1.CrossRefPubMedGoogle Scholar
  8. 8.
    Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006;39:469–78.CrossRefPubMedGoogle Scholar
  9. 9.
    Wey JS, Fan F, Gray MJ, Bauer TW, McCarty MF, Somcio R, et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer. 2005;104:427–38.CrossRefPubMedGoogle Scholar
  10. 10.
    Volm M, Koomagi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer. 1997;74:64–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Gomaa W, Ke Y, Fujii H, Helliwell T. Tissue microarray of head and neck squamous carcinoma: validation of the methodology for the study of cutaneous fatty acid-binding protein, vascular endothelial growth factor, involucrin and Ki-67. Virchows Arch. 2005;447:701–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Gomaa W, Al-Ahwal M, Hamour O, Al-Maghrabi J. Osteopontin cytoplasmic immunoexpression is a predictor of poor disease-free survival in thyroid cancer. J Microsc Ultrastruct. 2013;1:8–16.CrossRefGoogle Scholar
  13. 13.
    Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, Salama S, Al-Muhayawi S, Chaudhary A, et al. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Anticancer Res. 2011;31:4179–83.PubMedGoogle Scholar
  14. 14.
    Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66–70.CrossRefPubMedGoogle Scholar
  15. 15.
    Ning Q, Liu C, Hou L, Meng M, Zhang X, Luo M, et al. Vascular endothelial growth factor receptor-1 activation promotes migration and invasion of breast cancer cells through epithelial-mesenchymal transition. PLoS One. 2013;8:e65217.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost JTH. 2003;1:1356–70.CrossRefPubMedGoogle Scholar
  17. 17.
    Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, et al. Role of PLGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med. 2003;9:936–43.CrossRefPubMedGoogle Scholar
  18. 18.
    Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194–201.CrossRefPubMedGoogle Scholar
  19. 19.
    LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science. 2003;299:890–3.CrossRefPubMedGoogle Scholar
  20. 20.
    Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T, Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 2001;61:1207–13.PubMedGoogle Scholar
  21. 21.
    Dunk C, Ahmed A. Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells. Am J Pathol. 2001;158:265–73.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Okita NT, Yamada Y, Takahari D, Hirashima Y, Matsubara J, Kato K, et al. Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer. Jpn J Clin Oncol. 2009;39:595–600.CrossRefPubMedGoogle Scholar
  23. 23.
    Yin Y, Cao LY, Wu WQ, Li H, Jiang Y, Zhang HF. Blocking effects of siRNA on VEGF expression in human colorectal cancer cells. World J Gastroenterol. 2010;16:1086–92.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis—correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met. Tumour Biol. 2013;34:2109–17.CrossRefPubMedGoogle Scholar
  25. 25.
    Eppenberger M, Zlobec I, Baumhoer D, Terracciano L, Lugli A. Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer. BMC Cancer. 2010;10:93.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Yamaguchi T, Bando H, Mori T, Takahashi K, Matsumoto H, Yasutome M, et al. Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: association with progression and prognosis. Cancer Sci. 2007;98:405–10.CrossRefPubMedGoogle Scholar
  27. 27.
    Kopparapu PK, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, et al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res. 2013;33:2381–90.PubMedGoogle Scholar
  28. 28.
    Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene. 2005;24:2647–53.CrossRefPubMedGoogle Scholar
  29. 29.
    Wei SC, Tsao PN, Yu SC, Shun CT, Tsai-Wu JJ, Wu CH, et al. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut. 2005;54:666–72.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    von Marschall Z, Cramer T, Hocker M, Burde R, Plath T, Schirner M, et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology. 2000;119:1358–72.CrossRefGoogle Scholar
  31. 31.
    Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood. 2001;98:1904–13.CrossRefPubMedGoogle Scholar
  32. 32.
    La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol. 2003;34:18–27.CrossRefPubMedGoogle Scholar
  33. 33.
    Naik S, Dothager RS, Marasa J, Lewis CL, Piwnica-Worms D. Vascular endothelial growth factor receptor-1 is synthetic lethal to aberrant {beta}-catenin activation in colon cancer. Clin Cancer Res. 2009;15:7529–37.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Bates RC, Goldsmith JD, Bachelder RE, Brown C, Shibuya M, Oettgen P, et al. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol CB. 2003;13:1721–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Karaca Z, Tanriverdi F, Unluhizarci K, Ozturk F, Gokahmetoglu S, Elbuken G, et al. VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol Eur Fed Endocr Soc. 2011;164:277–84.CrossRefGoogle Scholar
  36. 36.
    Ghanem MA, van Steenbrugge GJ, Sudaryo MK, Mathoera RB, Nijman JM, van der Kwast TH. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (Flt-1) in nephroblastoma. J Clin Pathol. 2003;56:107–13.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Yao Y, Kubota T, Sato K, Kitai R, Takeuchi H, Arishima H. Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours. Acta Neurochir. 2001;143:159–66.CrossRefPubMedGoogle Scholar
  38. 38.
    Fine BA, Valente PT, Feinstein GI, Dey T. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol Oncol. 2000;76:33–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, et al. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer. 2006;106:1677–84.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Jaudah Al-Maghrabi
    • 1
    • 2
    • 5
  • Wafaey Gomaa
    • 1
    • 2
    • 4
  • Abdelbaset Buhmeida
    • 5
  • Yousif Qari
    • 3
  • Mohammad Al-Qahtani
    • 5
  • Mahmoud Al-Ahwal
    • 1
    • 3
  1. 1.Scientific Chair for Colorectal CancerKing Abdulaziz UniversityJeddahSaudi Arabia
  2. 2.Department of PathologyKing Abdulaziz UniversityJeddahSaudi Arabia
  3. 3.Department of MedicineKing Abdulaziz UniversityJeddahSaudi Arabia
  4. 4.Department of Pathology, Faculty of MedicineMinia UniversityEl MiniaEgypt
  5. 5.Center of Excellence in Genomic Medicine ResearchKing Abdulaziz UniversityJeddahSaudi Arabia

Personalised recommendations